Amarin Corp Plc (AMRN)

[dogn]

EVAPORATE study of IPE & low-attenuation plaque cited

MINI REVIEW article - Artificial Intelligence Advancements in the Cardiovascular Imaging of Coronary Atherosclerosis

https://www.frontiersin.org/articles/10.3389/fcvm.2022.839400/full

Front. Cardiovasc. Med., 21 March 2022

“There are a number of important ongoing applications of plaque quantification. Budoff et al. (35) demonstrated that in CAD patients with elevated triglyceride levels and already taking a statin, icosapent ethyl significantly decreased the volume of low-attenuation plaque compared to placebo over an 18 month period. The application of well-validated AI guided approach to atherosclerosis quantification may enable important advances in assessing the response to preventive therapies.”

35. Budoff MJ, Muhlestein JB, Bhatt DL, Le Pa VT, May HT, Shaikh K, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. Cardiovasc Res. (2021). 117:1070–7. doi: 10.1093/cvr/cvaa184

Not sure why authors didn’t cite final EVAPORATE results… available here:
https://academic.oup.com/eurheartj/article/41/40/3925/5898836